Cardioprotection thread, page-413

While there are many examples that I can use, this is a great paper to illustrate that point:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589555/pdf/medi-102-e35361.pdf

This paper was determining the prognostic value of FTO for the diagnosis of breast cancer. The table shows that FTO is upregulated in BC with advanced stage, size, and metastasis. This was the same across all BC types, as there was no significant difference between type. The reason the two French girls achieved a cure as children in advanced relapsed/refractory AML is because Bisantrene was able to abolish the m6A mRNA epitranscriptomic hardware controlling the cancers ability to avoid death. The women relapsed because cancer cells that had high levels of FTO were able to avoid death and grow again, and they were refractory because there was not another treatment that targeted the FTO pathway.

I know it is difficult science to wrap your head around, but investors need to remember that m6A modifications are the most abundant internal modification on eukaryotic mRNA. This means proteins like FTO are central to the transcription of 1000's of genes into proteins that mediate cellular function - cancer is mearly aberrant cellular function. This central control of cellular function is why you see associations between FTO and cancer and chemotherapy resistance/synergy, metabolic and neurological conditions, physiological systems, and many other things. Targeting this pathway is revolutionary for anti-cancer therapy, as it has never been done before, was discovered so recently, and is involved in so many cancer types as well as the hallmark functions.

If a farmer wants to pick apples, he doesn't pick the fruit, he shakes the tree. Oncologists have been picking fruit for years, now it's time to start shaking the tree.